1.
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor...
by Ruff, Christian T., MD
The American heart journal, 2010, Vol.160 (4), p.635-641.e2
2.
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
by Mega, Jessica L, Dr
The Lancet (British edition), 2015, Vol.385 (9984), p.2280-2287
3.
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial
by Magnuson, Elizabeth A., ScD
The American heart journal, 2015, Vol.170 (6), p.1140-1150
4.
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa N...
by Geller, Bram J., MD
The American heart journal, 2015, Vol.170 (4), p.669-674
5.
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation wit...
by Eisen, Alon, MD
The American heart journal, 2015, Vol.172, p.144-151
6.
Central versus local adjudication of myocardial infarction in a cardiac biomarker trial
by Smith, Stephen W., MD
The American heart journal, 2013, Vol.165 (3), p.273-279.e1
7.
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
by Ruff, Christian T, Dr
The Lancet (British edition), 2015, Vol.385 (9984), p.2288-2295
8.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
by Ruff, Christian T, Dr
The Lancet (British edition), 2014, Vol.383 (9921), p.955-962
